Should any changes be made to the inpatient care plan for an 18‑year‑old female with asthma presenting with acute shortness of breath, extensive pneumomediastinum, a negative esophagogram, currently receiving DuoNeb (albuterol + ipratropium bromide) nebulizations, intravenous methylprednisolone, piperacillin‑tazobactam, and a nil‑per‑os (NPO) order after midnight?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Changes to Care Plan

Yes, discontinue ipratropium bromide (the ipratropium component of DuoNeb) and discontinue piperacillin-tazobactam unless there is clear evidence of bacterial pneumonia. Additionally, clarify the indication for NPO status and consider allowing oral intake if the patient can tolerate it, given the negative esophagogram.

Critical Issues with Current Plan

1. Ipratropium Bromide Should Be Discontinued

The addition of ipratropium to albuterol has not been shown to provide further benefit once the patient is hospitalized 1, 2. The NAEPP guidelines explicitly state that ipratropium should be used only in the initial emergency department management for severe exacerbations (up to 3 hours), but provides no benefit after hospital admission 1, 2.

Recommended change:

  • Continue albuterol nebulizations alone (without ipratropium)
  • Continue methylprednisolone as appropriate for hospitalized asthma exacerbation
  • Continue respiratory therapy evaluation and treatment

2. Piperacillin-Tazobactam Requires Justification

There is no mention of bacterial pneumonia, infiltrate on imaging, or fever in this presentation. Pneumomediastinum from severe cough in asthma is a mechanical complication, not an infectious one 3, 4, 5. The case reports of similar presentations describe successful management with supportive care, bronchodilators, and corticosteroids alone—without antibiotics 3, 4, 5.

Recommended change:

  • Discontinue piperacillin-tazobactam unless there is documented evidence of:
    • Bacterial pneumonia on chest imaging
    • Fever or elevated inflammatory markers suggesting bacterial infection
    • Positive respiratory cultures
    • Other clear indication for broad-spectrum antibiotics

Common pitfall: Reflexively prescribing antibiotics for respiratory symptoms without bacterial infection increases antibiotic resistance and exposes patients to unnecessary adverse effects including Clostridioides difficile infection.

3. NPO Status Needs Clarification

The esophagogram showed no contrast extravasation, meaning esophageal perforation has been ruled out [@case presentation]. The NPO order "until midnight, then keep NPO after midnight" appears to be preparing for a potential procedure, but the indication is unclear.

Recommended approach:

  • If no procedure is planned and the patient can tolerate oral intake, allow oral diet
  • Oral corticosteroids are equally effective as IV formulations for asthma exacerbations when GI absorption is intact [@1@, 2]
  • Maintaining NPO status without clear indication risks:
    • Patient discomfort and decreased satisfaction
    • Unnecessary IV access maintenance
    • Delayed transition to oral medications

If surgical intervention is being considered: Clarify the specific indication and timing with cardiothoracic surgery

Appropriate Elements of Current Plan

The following should be continued:

  • Inpatient observation for pneumomediastinum monitoring (appropriate given extent of air)
  • Albuterol nebulizations (without ipratropium after initial ED period)
  • Methylprednisolone (systemic corticosteroids are the mainstay for asthma exacerbations) [@1@, 2]
  • Cardiothoracic surgery consultation and follow-up (appropriate for extensive pneumomediastinum)
  • Serial imaging to monitor for progression or development of pneumothorax [@5@, 4]
  • Supplemental oxygen if needed (facilitates nitrogen washout for pneumomediastinum) [@5@]

Monitoring Parameters

  • Serial chest radiographs to assess pneumomediastinum progression
  • Peak expiratory flow or FEV1 monitoring for asthma response
  • Oxygen saturation
  • Development of subcutaneous emphysema
  • Signs of tension pneumomediastinum (rare but serious): hemodynamic instability, worsening dyspnea

Expected Course

Spontaneous pneumomediastinum from asthma exacerbation typically resolves with conservative management over several days to weeks [@

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.